Navigation Links
ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen
Date:5/4/2011

ADDISON, Texas, May 4, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that it has filed a 510(k) application with the U.S. Food and Drug Administration to obtain marketing authorization for Altrazeal® Collagen.

Collagen containing wound care products represent a growing segment of the advanced wound care market. Collagen stimulates cellular migration and contributes to new tissue development. Collagen dressings encourage the deposition and organization of newly formed collagen, creating an environment that fosters healing. Biomaterials with collagen stimulate the wound healing cascade, recruiting specific cells during this process and ultimately, enhance wound healing.

Commenting on the Company's 510(k) application, Kerry P. Gray, President and CEO of ULURU Inc., stated, "Altrazeal® Collagen is an important line extension for our wound care franchise. Initial studies indicate that combining Altrazeal® with collagen provides accelerated wound healing compared to collagen alone, potentially providing additional synergistic benefits. The collagen market segment is a growing and important category within advanced wound care. Having Altrazeal® Collagen available will enable our sales representatives to provide an additional alternative therapy to the wound care professional to treat chronic wounds."

Mr. Gray continued, "The expansion of the Altrazeal® product line to include a collagen product and a silver containing product is an important component of our wound care strategy. Having this full compliment of products will enable us to more effectively compete in the major wound care market segments. Altrazeal® Collagen further enhances the value of the Company's Altrazeal® franchise and makes this asset more attractive to potential strategic partners."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended including our belief that wound care products containing collagen represent a growing market, our belief that Altrazeal® Collagen accelerates wound healing, and our ability to compete in the wound care market. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is expected to ... 2023 and reach a figure of $6.34 billion by ... disease and is affecting a huge population. Many technologies ... is focused on emerging cancer diagnostics market specifically on ... to factors such as: increasing number of cancer cases, ...
(Date:3/28/2017)... LAS VEGAS , March 28, 2017  Las ... first surgeries with XEN45 Gel Stent (Allergan, ... built up in the eye, thereby reducing intraocular pressure ... 60 million people globally are affected by glaucoma that ... in vision loss and blindness, if left untreated. ...
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent ... improve teacher quality, the field must first improve teacher preparation program design. It ... the next” and that decades of input- and outcome-based research has failed to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
Breaking Medicine News(10 mins):